RBI to issue new Rs 20 banknotes bearing Governor Sanjay Malhotra's signature
By Aditya Bhagchandani Published on May 17, 2025, 11:31 IST
The Reserve Bank of India (RBI) announced on Saturday, May 17, that it will soon issue new ₹20 denomination banknotes in the Mahatma Gandhi (New) Series. These notes will bear the signature of Shri Sanjay Malhotra, the recently appointed Governor of the central bank.
According to the RBI's press release, the design of the new ₹20 banknotes will remain the same as the existing Mahatma Gandhi (New) Series ₹20 notes. There will be no changes in design, color, or security features. All previous versions of ₹20 notes issued by the Reserve Bank will continue to be considered legal tender and remain in circulation alongside the new series.
This update is part of the RBI's regular issuance of banknotes with updated governor signatures. It does not impact the validity of existing currency notes of the same denomination already in the market.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion will focus on Jaguar's ongoing efforts to further its orphan disease development programs. Participation Instructions for Jaguar Health's Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series When: Tuesday, June 10, 2025 from 9:00 - 10:00 AM Eastern Where: Online (Click Here). The fireside chat will also be available for replay following the event. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners' spring 2025 Spotlight Series. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ SOURCE: Jaguar Health, Inc.
Yahoo
an hour ago
- Yahoo
India May inflation likely cooled to 3% as food price pressure eases
By Pranoy Krishna BENGALURU (Reuters) -India's consumer inflation rate likely eased to a more than six-year low of 3% in May thanks to a favourable base and a further moderation in food prices, a Reuters poll forecast, supporting last week's larger-than-expected interest rate cut. On Friday the Reserve Bank of India (RBI) stunned financial markets by slashing its key policy rate by 50 basis points, double what was predicted, to boost economic growth as inflation has remained subdued. The central bank, which targets inflation in the middle of its 2-6% range in the medium term, also shifted its policy stance to 'neutral' from 'accommodative'. A snap Reuters poll after the decision found the RBI was likely done with cutting rates, wrapping up one of its shortest and shallowest easing cycles in more than a decade. The June 5–9 Reuters poll of 50 economists, published on Monday, forecast inflation measured by the annual change in the consumer price index (CPI) fell even further to 3.00% in May from 3.16% in April. That would mark the fourth consecutive month below the RBI's 4.0% medium-term target, the longest such streak in nearly six years. It would also be the lowest inflation rate since April 2019, welcome news for many Indian households where food takes up a significant share of monthly expenses. Forecasts for the data due on Thursday at 1030 GMT ranged from 2.7% to 3.7%. "We are expecting a cooling of inflation to 3% on a combination of a favourable base effect and... sequential moderation in prices of cereals and pulses even as most other segments started to strengthen," said Kanika Pasricha, chief economic advisor at Union Bank of India. "Prices of most food segments though continue to slide but the pace of correction is losing ground," she added. While concerns over widespread heatwaves raised fears of an inflation spike last month, a healthy harvest and the early arrival of monsoon rains helped ease those risks. "Even though there were heatwaves, I think the early monsoons across the country are likely to have cooled things off... most of the categories of food inflation seem to be contained," said Indranil Pan, chief economist at Yes Bank. Core inflation, which strips out volatile food and energy items and is seen as a better indicator of domestic demand, was expected to have edged up to 4.20% year-on-year in May, from an estimated 4.00%-4.10% in April, the poll showed. India's official statistics agency does not publish core inflation data. Wholesale price index (WPI)-based inflation likely dipped to a 14-month low of 0.80% in May from 0.85% in April, the survey found. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
Indo Borax & Chemicals to launch Boron Oxide plant at Pithampur with Rs 20 crore investment
By Aditya Bhagchandani Published on June 9, 2025, 13:07 IST Indo Borax & Chemicals Ltd has announced the launch of a new high-value chemical product—Boron Oxide, with production set to commence in July 2025. As per its regulatory filing to the BSE and NSE dated June 9, 2025, the company aims to manufacture 4,000 metric tonnes per annum of Boron Oxide at its new facility being set up in Pithampur, Indore, Madhya Pradesh. The estimated capital expenditure for the project is Rs 20 crore, which will be financed through internal accruals. This new product will cater exclusively to the domestic market, leveraging Boric Acid—an existing product of the company—as a raw material. Notably, many customers for Boric Acid are also expected to be consumers of Boron Oxide, allowing for efficient market penetration. Indo Borax plans to reach full production capacity within a year in a phased manner. The Boron Oxide manufactured will be primarily used in the refractories sector, supporting industries that require high-performance materials. The company reaffirmed that this strategic move aligns with its intent to expand its product portfolio in high-margin chemical segments using existing operational strengths. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
